DK1971329T3 - TRIAZIN DERIVATIVES FOR USE IN A CICATRICIAL TREATMENT - Google Patents

TRIAZIN DERIVATIVES FOR USE IN A CICATRICIAL TREATMENT Download PDF

Info

Publication number
DK1971329T3
DK1971329T3 DK06829704.3T DK06829704T DK1971329T3 DK 1971329 T3 DK1971329 T3 DK 1971329T3 DK 06829704 T DK06829704 T DK 06829704T DK 1971329 T3 DK1971329 T3 DK 1971329T3
Authority
DK
Denmark
Prior art keywords
alkoxy
alkyl
aryl
optionally substituted
halogen
Prior art date
Application number
DK06829704.3T
Other languages
Danish (da)
English (en)
Inventor
Gérard Moinet
Daniel Cravo
Original Assignee
Poxel Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poxel Sas filed Critical Poxel Sas
Application granted granted Critical
Publication of DK1971329T3 publication Critical patent/DK1971329T3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D251/00Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK06829704.3T 2006-01-13 2006-12-18 TRIAZIN DERIVATIVES FOR USE IN A CICATRICIAL TREATMENT DK1971329T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0600347A FR2896161B1 (fr) 2006-01-13 2006-01-13 Utilisation de derives de triazines pour fabriquer un medicament ayant un effet cicatrisant ou angiogenique.
PCT/EP2006/012183 WO2007079915A2 (en) 2006-01-13 2006-12-18 Use of triazine derivatives for the manufacture of a medicament having a cicatrising or angiogenic effect

Publications (1)

Publication Number Publication Date
DK1971329T3 true DK1971329T3 (en) 2017-12-04

Family

ID=36658622

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06829704.3T DK1971329T3 (en) 2006-01-13 2006-12-18 TRIAZIN DERIVATIVES FOR USE IN A CICATRICIAL TREATMENT

Country Status (22)

Country Link
US (1) US8217040B2 (enExample)
EP (1) EP1971329B1 (enExample)
JP (1) JP2009523140A (enExample)
KR (1) KR101482686B1 (enExample)
CN (1) CN101355931A (enExample)
AR (1) AR059034A1 (enExample)
AU (1) AU2006334732B2 (enExample)
BR (1) BRPI0620983B8 (enExample)
CA (1) CA2636838C (enExample)
CY (1) CY1119872T1 (enExample)
DK (1) DK1971329T3 (enExample)
EA (1) EA016127B1 (enExample)
ES (1) ES2647912T3 (enExample)
FR (1) FR2896161B1 (enExample)
HU (1) HUE037217T2 (enExample)
IL (1) IL192595A (enExample)
LT (1) LT1971329T (enExample)
PL (1) PL1971329T3 (enExample)
PT (1) PT1971329T (enExample)
SI (1) SI1971329T1 (enExample)
WO (1) WO2007079915A2 (enExample)
ZA (1) ZA200806946B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2948027A1 (fr) * 2009-07-17 2011-01-21 Merck Sante Sas Derives amines de dihydro-1,3,5-triazine pour leur utilisation dans le traitement des maladies associees a une ischemie et/ou une reperfusion
JP2020536121A (ja) 2017-10-02 2020-12-10 ポクセルPoxel 駆出率が保持された心不全を治療する方法
CA3102412A1 (en) 2018-06-06 2019-12-12 Metavant Sciences Gmbh Methods of treating subjects having diabetes with chronic kidney disease
WO2019238647A1 (en) 2018-06-14 2019-12-19 Poxel Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes
EP4014962A1 (de) * 2020-12-16 2022-06-22 Novigo GmbH & Co. KG Zusammensetzung mit osmotisch wirksamer substanz und verwendung der zusammensetzung
FR3149774B1 (fr) * 2024-01-11 2025-06-20 Fabre Pierre Dermo Cosmetique 5,6,5’,6’-tétraphényl-3,3’-(1,4-phénylène)-bis[1,2,4]triazine pour améliorer l’aspect des cicatrices et/ou réduire les marques cicatricielles

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150362A (en) * 1997-12-12 2000-11-21 Henkin; Jack Triazine angiogenesis inhibitors
DK1037886T3 (da) * 1997-12-12 2003-08-25 Abbott Lab Triazin angiogeneseinhibitorer
FR2804113B1 (fr) * 2000-01-26 2004-06-18 Lipha Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique
AU2003289375A1 (en) * 2002-12-17 2004-07-09 Hamari Chemicals, Ltd Novel 2,4-diamino-1,3,5-triazine derivative
FR2853650B1 (fr) * 2003-04-10 2006-07-07 Merck Sante Sas Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance

Also Published As

Publication number Publication date
SI1971329T1 (en) 2018-03-30
WO2007079915A2 (en) 2007-07-19
BRPI0620983B8 (pt) 2021-05-25
JP2009523140A (ja) 2009-06-18
ZA200806946B (en) 2009-11-25
BRPI0620983A2 (pt) 2011-11-29
AU2006334732B2 (en) 2012-05-17
CN101355931A (zh) 2009-01-28
EP1971329A2 (en) 2008-09-24
CA2636838A1 (en) 2007-07-19
PT1971329T (pt) 2017-11-24
ES2647912T3 (es) 2017-12-27
PL1971329T3 (pl) 2018-03-30
EP1971329B1 (en) 2017-10-11
HUE037217T2 (hu) 2018-08-28
AR059034A1 (es) 2008-03-12
EA200801678A1 (ru) 2008-12-30
EA016127B1 (ru) 2012-02-28
KR101482686B1 (ko) 2015-01-14
BRPI0620983B1 (pt) 2019-09-17
FR2896161B1 (fr) 2008-04-04
LT1971329T (lt) 2018-01-25
WO2007079915A3 (en) 2007-08-30
IL192595A0 (en) 2009-02-11
IL192595A (en) 2013-04-30
US20100168115A1 (en) 2010-07-01
CA2636838C (en) 2015-05-05
FR2896161A1 (fr) 2007-07-20
US8217040B2 (en) 2012-07-10
AU2006334732A1 (en) 2007-07-19
KR20080088629A (ko) 2008-10-02
CY1119872T1 (el) 2018-06-27

Similar Documents

Publication Publication Date Title
JP5688405B2 (ja) 抗真菌医薬組成物
AU2001264011B2 (en) Use of biguanide derivatives for making a medicine having a wound healing effect
Türkyılmaz et al. Mitomycin C prevents strictures in caustic esophageal burns in rats
DK1971329T3 (en) TRIAZIN DERIVATIVES FOR USE IN A CICATRICIAL TREATMENT
US9572777B2 (en) Topical pharmaceutical composition comprising nanonized silver sulfadiazine
NO20060650L (no) Kinazolinderivater som angiogeneseinhibitorer
WO2009099405A2 (en) Antibacterial compositions and methods of treatment
US20190142721A1 (en) Composition containing substance for regulating expresson of abh antigens
JP4155430B2 (ja) 皮膚老化抑制剤およびその用途
KR102081003B1 (ko) 수베르산을 유효성분으로 포함하는 탈모 방지 또는 발모 촉진용 조성물
HK1128406A (en) Use of triazine derivatives for the manufacture of a medicament having a cicatrising or angiogenic effect
KR20130077953A (ko) 카르노스산 또는 그 유도체를 함유하는 엘라스테이즈 활성 저해제
CN112334131B (zh) 包含靛玉红衍生物作为活性成分的药物组合物
JP5555922B2 (ja) 脱毛を治療する、又は、脱毛の発症を遅らせるための組成物
US10398664B2 (en) Methods of diagnosing and treating infected implants
TW202228715A (zh) 自噬活化劑
KR20250108066A (ko) 튜불린 저해제를 포함하는 병용요법을 이용한 피부 질환 예방 또는 치료용 조성물
DE102012103717A1 (de) Arzneimittel zur Behandlung von Tumorerkrankungen
KR20160044214A (ko) Abh 항원의 발현을 조절하는 물질을 포함하는 모공 축소용 조성물
CA3106105A1 (en) Methods of diagnosing and treating infected implants
Kumar Wound healing effect of alcoholic extract of Ocimum sanctum linn. on rats
HK1231396B (zh) 外用组合物